Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart disease
Biotech
Novo Nordisk shares mixed data behind pivotal heart disease push
Neither coramitug cohort performed better than the placebo arm on the six-minute walk test, causing the trial to miss one of its primary endpoints.
Nick Paul Taylor
Nov 11, 2025 8:32am
Braveheart, with Biogen CEO on board, rallies $185M series A
Nov 5, 2025 7:51am
Kardigan fashions $254M series B for late-stage pipeline
Oct 14, 2025 9:00am
Braveheart pays $65M to challenge BMS for heart disease market
Sep 5, 2025 9:05am
Corsera launches with $50M for predictive AI tool, RNAi asset
Sep 2, 2025 6:30am
Sanofi scoops up China rights to Cytokinetics' heart disease med
Dec 20, 2024 11:07am
